You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3
  1. Harshna Patel,
  2. E Jenny Heathcote
  1. Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr Jenny Heathcote, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst St, 6FP, Rm 154, Toronto, Ontario, Canada, M5T 2S8; jenny.heathcote{at}utoronto.ca

https://doi.org/10.1136/gut.2010.217323

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the paper by Himmelsbach and colleagues discussing the role of sorafenib in blocking hepatitis C virus (HCV) replication in vitro.1 Further studies are required to delineate the potential antiviral efficacy either in combination with the standard of care (Peg-IFN and ribavirin) or as monotherapy. Currently, a number of new antiviral drugs are being investigated in order to improve sustained virological response (SVR) rates and/or reduce treatment duration in chronic hepatitis C (CHC). However, to date none of the new small molecule drugs appear effective against genotype 3 such that at the present time patients with genotype 3 infection have no other options.

    Debio 025 is a selective cyclophilin inhibitor that has previously demonstrated antiviral activity against the hepatitis C virus both in vitro and in vivo.2 3 Results of a phase Ib study indicate that Debio 025 has an important additive anti-HCV effect when coadministered with Peg-interferon (IFN)α-2a to treatment-naive patients …

    View Full Text

    Footnotes

    • Linked articles 212068.

    • Funding The project from which this case is taken was funded by Debio Pharm and their approval has been obtained for this case report (Dr. R. Crabbe). Dr. Jenny Heathcote has commercial associations with the following: Hoffmann LaRoche, Schering-Plough, Axcan-Pharma, Gilead Sciences, GlaxoSmithKline, Human Genome Sciences, Novartis, Idenix, Vertex, Bristol Myers Squibb, Pharmasset, Debiopharm, Boerhinger Ingleheim and Tibotec.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval This study was conducted with the approval of the Toronto Western Hospital.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles